By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later ...

European stocks logged their biggest one-day drop in over three months on Friday, at the end of a busy week as investors ...

A MUM almost died on the way to her son’s wedding after using weight loss jabs to look “thin” in wedding snaps. Ali Eastburn ...

Shares in European pharmaceutical firms slumped following a threat by President Donald Trump to punish them if they don't ...

Novo Nordisk's shares have experienced a significant decline due to increasing competition and pressure from the U.S.

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.

Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions ...

Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.

For a while, Danish drugmaker Novo Nordisk A/S looked unstoppable. It was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat ...